The Clinical Efficacy of MINE Regimen for the Treatment on 23 Case of Recurrent and Refractory Non Hodgkin's Lymphoma

Objective 　To observe the antitumor effect and toxicities of MINE regimen based on mitoxantron, etoposide, ifosfamide in the patients with recurrent and ref ractory non-Hodgkin's lymphoma. Methods 　Total of 23 patient s failing to respond to CHOP regimen were t reated with MINE regimen and every patient had gotten at least 2 cycles t reatment . MIT 6～8mg/ m2 / d, IV on d1 ; IFO 2. 0 IV on d1～3, combined with mesna 400mg IV for 3 times (0h、4h、8h), d1～3 ;VP16 80mg/ m2 / d, IV on d1～3 。The therapeutic effect s and toxicity were evaluated according to the WHO criteria. Results 　In 23 patient s, 65. 2 % of response rate were achieved with 5 case CR, 10 case PR, 3 case SD, 5 case PD. Main side-effect was myelosuppression. Neutropenia was reported in 73. 9 % of patient s and it was mostly Grade Ⅰ/ Ⅱ. All of them got G-CSF treatment and the counts of white blood cells became normal. No patient died of toxicity related to chemotherapy. Conclusion 　MINE regimen has a safe and higher therapeutic effect on resistant patient s with NHL.